Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.468 EUR
−23.49 M EUR
0.00 EUR
9.84 M
About PHAXIAM THERAPEUTICS
Sector
CEO
Thibaut du Fayet
Headquarters
Lyon
Website
Founded
2004
ISIN
FR001400K4B1
FIGI
BBG00NRVY2C6
PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0QSS is 1.586 EUR — it has decreased by −19.00% in the past 24 hours. Watch PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) stocks are traded under the ticker 0QSS.
0QSS stock has fallen by −19.00% compared to the previous week, the month change is a −13.80% fall, over the last year PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) has showed a −62.66% decrease.
We've gathered analysts' opinions on PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) future price: according to them, 0QSS price has a max estimate of 5.30 EUR and a min estimate of 4.90 EUR. Watch 0QSS chart and read a more detailed PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) stock forecast: see what analysts think of PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) and suggest that you do with its stocks.
0QSS reached its all-time high on Apr 30, 2020 with the price of 96.636 EUR, and its all-time low was 1.602 EUR and was reached on Nov 4, 2024. View more price dynamics on 0QSS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0QSS stock is 24.40% volatile and has beta coefficient of 0.15. Track PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) stock price on the chart and check out the list of the most volatile stocks — is PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) there?
Today PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) has the market capitalization of 16.70 M, it has decreased by −4.76% over the last week.
Yes, you can track PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) financials in yearly and quarterly reports right on TradingView.
PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
0QSS net income for the last half-year is −10.63 M EUR, while the previous report showed −11.29 M EUR of net income which accounts for 5.78% change. Track more PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) financial stats to get the full picture.
No, 0QSS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 68.00 employees. See our rating of the largest employees — is PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) on this list?
Like other stocks, 0QSS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) stock shows the sell signal. See more of PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.